What happened with STTK today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Shattuck Labs is a clinical-stage biotechnology company focused on blocking DR3, a target involved in inflammatory and immune-mediated diseases. Its lead candidate, SL-325, is an antibody being tested in healthy volunteers in a Phase 1 trial. The business depends heavily on successfully developing this candidate and securing regulatory approval before it can be sold. The company has no approved products and has never generated drug-sales revenue.
Kayak holds an exclusive license to Shattuck’s oncology-focused TRIM7 program. Shattuck received Kayak preferred stock, rather than cash, as the upfront payment. It may also receive payments if development, regulatory and commercial milestones are met, plus royalties if resulting products reach the market. These potential payments are not assured; Shattuck has primarily funded its operations through securities sales and collaboration agreements.
Shattuck also depends on outside manufacturers to supply its experimental drugs. Kemwell Biopharma Private Limited is its sole contract manufacturer for SL-325 bulk drug substance, making that supplier important to keeping development supplied.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Shattuck’s prospects hinge on proving DR3 blockade works clinically and stands apart from TL1A rivals, including Roche’s afimkibart, which is absent from this list.
Spyre Therapeutics challenges Shattuck’s DR3-blocking antibodies and dual-target approach with long-acting TL1A antibodies and combinations for inflammatory diseases. Watch whether its inflammatory bowel disease programs can deliver the proposed quarterly or twice-yearly maintenance injections.
Xencor’s XmAb942 targets TL1A while Shattuck’s antibodies block DR3, offering competing ways to inhibit the same inflammatory pathway. For Shattuck holders, XmAb942’s clinical progress matters more directly than Xencor’s revenue from partners paying for drug rights, milestones and royalties.
Aclaris Therapeutics competes with Shattuck’s DR3/TL1A-pathway programs through bosakitug, an antibody targeting TL1A, and ATI-052, an antibody targeting TL1A and a second target.
Teva’s duvakitug competes with Shattuck’s SL-325 by blocking TL1A rather than the receptor it binds to, DR3. Duvakitug’s clinical progress is the relevant comparison for SL-325, rather than Teva’s broader sales of generic and innovative medicines.
Merck’s tulisokibart clinical results help gauge the competition facing Shattuck’s DR3-blocking antibodies because tulisokibart blocks TL1A in the same pathway. Watch those results rather than Merck’s overall sales of medicines, vaccines and animal health products.
AbbVie’s ABBV-701 and Shattuck’s SL-325 compete to block the same inflammatory pathway: ABBV-701 targets TL1A, while SL-325 targets its receptor, DR3. ABBV-701’s development is the specific program to watch when judging how Shattuck’s approach differs.
Sanofi co-develops duvakitug with Teva to block TL1A, putting that program in competition with Shattuck’s approach of blocking DR3 in the same inflammatory pathway.
Merck & Co., Inc. earningsMRK
Merck's report will show how its TL1A-blocking antibody tulisokibart is progressing clinically, offering a read on competition for Shattuck Labs' DR3-blocking approach.
Focus on tulisokibart's clinical progress, not Merck's overall medicine sales. Continued progress would show that a TL1A-blocking approach in the same inflammatory pathway is advancing, raising the need for Shattuck to show what its DR3-blocking SL-325 does differently; setbacks would weaken evidence for this competing approach, but would not establish that SL-325 works.
Shattuck Labs, Inc. earningsThis company
Shattuck Labs has no product sales and relies on financing to fund development, so this report will show whether SL-325 is advancing in its Phase 1 trial alongside the cash the company uses to develop it.
Read SL-325's Phase 1 progress alongside cash used in operations. Trial progress with cash use kept in check would show that Shattuck's lead program is advancing while its funding supports development; little progress as cash continues to go out would mean spending has not yet translated into visible progress, increasing the importance of future financing.
